Hyperphosphatemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Hyperphosphatemia Market Outlook

Thelansis’s “Hyperphosphatemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperphosphatemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hyperphosphatemia Overview

Elevated serum phosphorus levels of hyperphosphatemia are defined as surpassing 4.5 mg/dL, with severe cases categorized by levels exceeding 14 mg/dL. Renal failure is the predominant cause, primarily attributed to a glomerular filtration rate below 30 mL/min, which diminishes inorganic phosphate filtration, elevating serum levels. Additional less frequent contributors encompass heightened phosphorus intake and increased renal reabsorption. Excessive phosphate ingestion may result from the overuse of phosphate-containing laxatives or enemas, coupled with vitamin D intoxication, which enhances intestinal phosphate absorption. Conditions such as hypoparathyroidism, acromegaly, and thyrotoxicosis intensify renal phosphate reabsorption, contributing to hyperphosphatemia. Genetic factors also play a role, with deficiencies leading to hypoparathyroidism, pseudohypoparathyroidism, and decreased FGF-23 activity. The guidelines for Kidney Disease: Improving Global Outcomes (KDIGO) recommend reducing phosphate levels in dialysis patients toward the normal range without specifying a target level. Maintaining serum phosphate levels within the normal range (below 4.5 mg/dL [1.45 mmol/L]) is advised for non-dialysis chronic kidney disease patients. Effective control involves managing secondary hyperparathyroidism with vitamin D metabolites and calcium-sensing receptor agonists. Xphozah, FDA-approved for adults with chronic kidney disease on dialysis, serves as an adjunct therapy for those with an insufficient response to phosphate binders. Typically asymptomatic, hyperphosphatemia's mortality stems from underlying conditions. Short-term complications encompass tetany due to hypocalcemia and the deposition of calcium/phosphate in soft tissues, subcutaneous tissues, and joints.

• Conversely, hypophosphatemia is prevalent in up to 34% of patients post-elective cardiac surgery, with a notably high incidence after major hepatic surgery, where nearly all patients experience hypophosphatemia within the initial postoperative week.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: